Lurasidone HCL (Latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with Schizophrenia

P and T

Volumn 36, Issue 8, 2011, Pages 489-492

  Cruz, Martin P ^a,b,c,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAMPTON UNIVERSITY   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d Hampton VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DIGOXIN; DILTIAZEM; KETOCONAZOLE; LITHIUM; LURASIDONE; MIDAZOLAM; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RIFAMPICIN;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; BREAST FEEDING; BRIEF PSYCHIATRIC RATING SCALE; CREATININE CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; HUMAN; LEUKOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PARKINSONISM; PATIENT MONITORING; PREGNANCY; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; SUICIDAL IDEATION; SYNCOPE; TABLET;

EID: 80052593267     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. U.S. Census Bureau, Population, Division. Estimates by Demographic Characteristics. June 9, 2005. Available at www.census.gov/popest/national/asrh/nc-est 2004/nc-est2004-02.xls. Accessed May 25, 2011.
2. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, D.C.: American Psychiatric Association; 1994: 285.
3. Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: The Free Press; 1991.
4. Wu EQ, Birnbaum HG, Shi L. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-1129.
5. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizo phrenia: Initial validation. J Nerv Ment Dis 1994;182:631.
6. Breier A, Berg PH. The psychosis of schizophrenia: Prevalence, response to typical antipsychotics, and prediction of outcome. Biol Psychiatry 1999;46:361.
7. Applebaum PS, Robbins PC, Roth LH. Dimensional approach to delusions: Comparison across types and diagnoses. Am J Psychiatry 1999;156:1938.
8. Kitamura, T, Okazaki, Y, Fujinawa, A, et al. Dimensions of schizophrenic positive symptoms: An exploratory factor analysis investigation. Eur Arch Psychiatry Clin Neurosci 1998;248:130.
9. Andreasen NC. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 1982;39:784.
10. Saykin AJ, Gur RC, Gur RE, et al. Neuro - psychological function in schizophrenia: Selective impairment in memory and learning. Arch Gen Psychiatry 1991;48: 618.
11. Edwards J, Jackson HJ, Pattison PE. Emotion recognition via facial expression and affective prosody in schizophrenia: A methodological review. Clin Psychol Rev 2002;22:789.
12. Hirsch SR, Jolley A, Barnes T. Are depressive symptoms part of the schizophrenic syndrome? In: DeLisi L, ed. De pression in Schizophrenia. Washington, D.C.: American Psychiatric Press; 1990:25.
13. Meltzer HY. Outcome in schizophrenia: Beyond symptom reduction. J Clin Psychiatry 1999(60 Suppl 3):3.
14. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; 47:27.
15. Latuda (lurasidone), product information: Fort Lee, N.J.: Sunovion; 2010.